Effective Immunoconjugate Therapy in Cancer Models Targeting a Serine Protease of Tumor Fibroblasts

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Clinical Cancer Research

• Publication date

  2008-07-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-07-5211PMID 18628473
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Monoclonal Antibodies in the Treatment of Non-Hodgkin’s Lymphoma

  2012cited by this paper
• Monoclonal antibody-based therapeutics for leukemia

  2007cited by this paper
• Identification and expansion of human colon-cancer-initiating cells

  2007cited by this paper
• A human colon cancer cell capable of initiating tumour growth in immunodeficient mice

  2007cited by this paper
• Expression of stromal cell markers in distinct compartments of human skin cancers

  2006cited by this paper
• Fibroblasts in cancer

  2006cited by this paper
• Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing.

  2006cited by this paper
• Antibody targeted drugs as cancer therapeutics

  2006cited by this paper
• Comparing antibody and small-molecule therapies for cancer

  2006cited by this paper
• Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein.

  2006cited by this paper
• Antibody-drug conjugates designed to eradicate tumors with homogeneous and heterogeneous expression of the target antigen.

  2006cited by this paper
• Semisynthetic maytansine analogues for the targeted treatment of cancer.

  2006cited by this paper
• Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

  2005cited by this paper
• Monoclonal antibody successes in the clinic

  2005cited by this paper
• Supplemental Data Stromal Fibroblasts Present in Invasive Human Breast Carcinomas Promote Tumor Growth and Angiogenesis through Elevated SDF-1/CXCL12 Secretion

  2005cited by this paper
• Molecular requirements for epithelial-mesenchymal transition during tumor progression.

  2005cited by this paper
• Therapeutic targeting of the tumor microenvironment.

  2005cited by this paper
• Arming antibodies: prospects and challenges for immunoconjugates

  2005cited by this paper
• Characterization of cancer stroma markers: in silico analysis of an mRNA expression database for fibroblast activation protein and endosialin.

  2005cited by this paper
• Drug-conjugated monoclonal antibodies for the treatment of cancer.

  2005cited by this paper
• Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.

  2005cited by this paper
• Microarray-based Detection of Multidrug Resistance in Human Tumor Cells by Expression Profiling of ATP-binding Cassette Transporter Genes

  2004cited by this paper
• Pharmacokinetics and Biodistribution of the Antitumor Immunoconjugate, Cantuzumab Mertansine (huC242-DM1), and Its Two Components in Mice

  2004cited by this paper
• Friends or foes — bipolar effects of the tumour stroma in cancer

  2004cited by this paper
• A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer.

  2003cited by this paper
• Fibroblast activation protein: differential expression and serine protease activity in reactive stromal fibroblasts of melanocytic skin tumors.

  2003cited by this paper
• Expression and targeting of human fibroblast activation protein in a human skin/severe combined immunodeficient mouse breast cancer xenograft model.

  2003cited by this paper
• Contents of Next Issues · Themenvorschau

  2002cited by this paper
• Expression of the fibroblast activation protein during mouse embryo development.

  2001cited by this paper
• Targeted Disruption of Mouse Fibroblast Activation Protein

  2000cited by this paper
• Fibroblast Activation Protein, a Dual Specificity Serine Protease Expressed in Reactive Human Tumor Stromal Fibroblasts*

  1999cited by this paper
• Mouse fibroblast‐activation protein

  1998cited by this paper
• Mouse fibroblast-activation protein--conserved Fap gene organization and biochemical function as a serine protease.

  1998cited by this paper
• Mouse fibroblast activation protein: Molecular cloning, alternative splicing and expression in the reactive stroma of epithelial cancers

  1997cited by this paper
• The thyroid hormone-induced tail resorption program during Xenopus laevis metamorphosis.

  1996cited by this paper
• Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers.

  1994cited by this paper
• Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts.

  1994cited by this paper
• Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin.

  1993cited by this paper
• Immunoconjugates containing novel maytansinoids: promising anticancer drugs.

  1992cited by this paper
• Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers.

  1990cited by this paper
• Correlation of drug response in patients and in the clonogenic assay with solid human tumour xenografts.

  1990cited by this paper
• Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells.

  1988cited by this paper

• Identification of cancer-associated fibroblast characteristics for predicting outcome and response to immunotherapy in renal cell carcinoma.

  2025cites this paper
• Decoding tumors from fibroblast activation protein: A review of the latest diagnostic and therapeutic prospects.

  2025cites this paper
• Cancer-associated fibroblasts in the tumor microenvironment: heterogeneity, crosstalk mechanisms, and therapeutic implications

  2025cites this paper
• Theranostic Potential of [68Ga]Ga/[177Lu]Lu-LNC1013: A Dual-Purpose Ligand for Cancer Imaging and Radionuclide Therapy.

  2025cites this paper
• Scrambled RGD Hexameric Peptide Hydrogel Supports Efficient Self‐Assembly and Cell Activity

  2025cites this paper
• Revisiting the role of cancer-associated fibroblasts in tumor microenvironment

  2025cites this paper
• Stem-Cell Niches in Health and Disease: Microenvironmental Determinants of Regeneration and Pathology

  2025cites this paper
• Leveraging selection for function in tumor evolution: System-level cancer therapies

  2025cites this paper
• Cancer-associated fibroblasts in carcinogenesis

  2025cites this paper
• Cancer-associated fibroblasts as therapeutic targets for cancer: advances, challenges, and future prospects

  2025cites this paper
• CANCER-ASSOCIATED FIBROBLASTS Cafs: A NEW CHALLENGE FOR PATHOLOGISTS AND ONCOLOGISTS, AND A PROMISING TARGET FOR A MODERN ONCOTHERAPY

  2024cites this paper
• In vivo activation of FAP-cleavable small molecule-drug conjugates for the targeted delivery of camptothecins and tubulin poisons to the tumor microenvironment.

  2024cites this paper
• Cancer-associated fibroblasts, tumor and radiotherapy: interactions in the tumor micro-environment

  2024cites this paper
• Co-expression patterns of cancer associated fibroblast markers reveal distinct subgroups related to patient survival in oropharyngeal squamous cell carcinoma

  2024cites this paper
• Extracellular matrix stiffness and tumor-associated macrophage polarization: new fields affecting immune exclusion

  2024cites this paper
• Endogenous bystander killing mechanisms enhance the activity of novel FAP‐specific CAR‐T cells against glioblastoma

  2024cites this paper
• TALEN-edited allogeneic inducible dual CAR T cells enable effective targeting of solid tumors while mitigating off-tumor toxicity

  2024cites this paper
• Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma therapy: Challenges and opportunities.

  2024cites this paper
• Beyond Small Molecules: Antibodies and Peptides for Fibroblast Activation Protein Targeting Radiopharmaceuticals

  2024cites this paper
• Current evidence on the role of fibroblasts in large-vessel vasculitides: From pathogenesis to therapeutics.

  2024cites this paper
• Cancer-associated fibroblasts: a versatile mediator in tumor progression, metastasis, and targeted therapy

  2024cites this paper
• Integrated transcriptomics identifies prognostic significance and therapeutic response of cancer-associated fibroblast subpopulations in ovarian cancer

  2024cites this paper
• CAR T-cells for pediatric solid tumors: where to go from here?

  2024cites this paper
• Integrated transcriptomic analysis systematically reveals the heterogeneity and molecular characterization of cancer-associated fibroblasts in osteosarcoma.

  2024cites this paper
• Targeting fibroblast activation protein (FAP): advances in CAR-T cell, antibody, and vaccine in cancer immunotherapy

  2023cites this paper
• Mechanical stiffness promotes skin fibrosis through FAPα-AKT signaling pathway.

  2023cites this paper
• Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy

  2023cites this paper
• MOFs-Based Nanoagents Enable Sequential Damage to Cancer-Associated Fibroblast and Tumor Cells for Phototriggered Tumor Microenvironment Regulation.

  2023cites this paper
• Synthesis, radiolabeling, and evaluation of a (4-quinolinoyl)glycyl-2-cyanopyrrolidine analogue for fibroblast activation protein (FAP) PET imaging

  2023cites this paper
• FAP is a prognostic marker, but not a viable therapeutic target for clinical translation in HNSCC

  2023cites this paper
• Self‐Adaptive Nanoregulator to Mitigate Dynamic Immune Evasion of Pancreatic Cancer

  2023cites this paper
• Cancer-Associated Fibroblast Heterogeneity and Its Influence on the Extracellular Matrix and the Tumor Microenvironment

  2023cites this paper
• Specific Subtypes of Carcinoma-Associated Fibroblasts Are Correlated with Worse Survival in Resectable Pancreatic Ductal Adenocarcinoma

  2023cites this paper
• Antibody–Drug Conjugates: Ushering in a New Era of Cancer Therapy

  2023cites this paper
• Exploring the dynamic interplay between cancer stem cells and the tumor microenvironment: implications for novel therapeutic strategies

  2023cites this paper
• Fibroblast Activation Protein Inhibitor–Based Radionuclide Therapies: Current Status and Future Directions

  2023cites this paper
• Advanced Fibroblast Activation Protein-Ligand Developments: FAP Imaging Agents: A Review of the Structural Requirements.

  2023cites this paper
• Heterogeneity of cancer-associated fibroblasts in head and neck squamous cell carcinoma

  2023cites this paper
• Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels the heterogeneity of cancer-associated fibroblasts in TNBC

  2023cites this paper
• Fibroblast Activation Protein Expression in Sarcomas

  2023cites this paper
• Cancer-associated Fibroblasts in Neoadjuvant Setting for Solid Cancers.

  2023cites this paper
• A Tumor‐Microenvironment‐Activatable Molecular Pro‐Theranostic Agent for Photodynamic and Immunotherapy of Cancer

  2023cites this paper
• The Role of Different Immunocompetent Cell Populations in the Pathogenesis of Head and Neck Cancer—Regulatory Mechanisms of Pro- and Anti-Cancer Activity and Their Impact on Immunotherapy

  2023cites this paper
• Define cancer-associated fibroblasts (CAFs) in the tumor microenvironment: new opportunities in cancer immunotherapy and advances in clinical trials

  2023cites this paper
• Fibroblast Activation Protein Inhibitor Theranostics.

  2022cites this paper
• Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond

  2022cites this paper
• The importance of being CAFs (in cancer resistance to targeted therapies)

  2022cites this paper
• New Technologies Bloom Together for Bettering Cancer Drug Conjugates

  2022cites this paper
• Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine.

  2022cites this paper
• Advances in CAR-T Cell Genetic Engineering Strategies to Overcome Hurdles in Solid Tumors Treatment

  2022cites this paper
• New Technologies Bloom Together for Bettering Cancer Drug Conjugates

  2022cites this paper
• Cancer‐associated fibroblasts in breast cancer: Challenges and opportunities

  2022cites this paper
• Role of Serine Proteases at the Tumor-Stroma Interface

  2022cites this paper
• Targeting Tumour-Associated Fibroblasts in Cancers

  2022cites this paper
• The heterogeneity of cancer‐associated fibroblast subpopulations: Their origins, biomarkers, and roles in the tumor microenvironment

  2022cites this paper
• Cancer-associated fibroblasts and resistance to anticancer therapies: status, mechanisms, and countermeasures

  2022cites this paper
• Targeting cancer-associated fibroblasts: Challenges, opportunities and future directions.

  2022cites this paper
• Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy

  2022cites this paper
• Cancer-Associated Fibroblasts: Tumorigenicity and Targeting for Cancer Therapy

  2022cites this paper
• Cancer-associated Fibroblasts: Origin, Function, Imaging, and Therapeutic Targeting.

  2022cites this paper
• Cancer-Associated Fibroblasts in the Hypoxic Tumor Microenvironment

  2022cites this paper
• A review on targeting tumor microenvironment: The main paradigm shift in the mAb-based immunotherapy of solid tumors.

  2022cites this paper
• Evaluating near‐infrared photoimmunotherapy for targeting fibroblast activation protein‐α expressing cells in vitro and in vivo

  2022cites this paper
• Bête Noire of Chemotherapy and Targeted Therapy: CAF-Mediated Resistance

  2022cites this paper
• Modulating Tumor Physical Microenvironment for Fueling CAR-T Cell Therapy.

  2022cites this paper
• Dual Role of Fibroblasts Educated by Tumour in Cancer Behavior and Therapeutic Perspectives

  2022cites this paper
• HPV status represents dominant trait driving delineation of survival-associated gene co-expression networks in head and neck cancer

  2022cites this paper
• Highlights of Strategies Targeting Fibroblasts for Novel Therapies for Rheumatoid Arthritis

  2022cites this paper
• Fibroblast activation protein-based theranostics in pancreatic cancer

  2022cites this paper
• Modulation of the antitumor immune response by cancer-associated fibroblasts: mechanisms and targeting strategies to hamper their immunosuppressive functions

  2022cites this paper
• Cell type and gene expression deconvolution with BayesPrism enables Bayesian integrative analysis across bulk and single-cell RNA sequencing in oncology

  2022cites this paper
• Synthesis and Preliminary Evaluation of 131I-Labeled FAPI Tracers for Cancer Theranostics.

  2021cites this paper
• Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives

  2021cites this paper
• Cancer‐associated fibroblasts: Key players in shaping the tumor immune microenvironment

  2021cites this paper
• The tumor microenvironment as driver of stemness and therapeutic resistance in breast cancer: New challenges and therapeutic opportunities

  2021cites this paper
• Engineered exosome-like nanovesicles suppress tumor growth by reprogramming tumor microenvironment and promoting tumor ferroptosis.

  2021cites this paper
• Eliminating fibroblast activation protein-α expressing cells by photoimmunotheranostics

  2021cites this paper
• Other cells of the tumor microenvironment

  2021cites this paper
• New Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors: A Rational Review and Current Progress

  2021cites this paper
• SP13786通过CAFs外泌体抑制Stat3-EMT影响肺腺癌细胞A549的迁移侵袭

  2021cites this paper
• Next-generation immunotherapy for pancreatic ductal adenocarcinoma: navigating pathways of immune resistance

  2021cites this paper
• Role of cancer‐associated fibroblast subpopulations in immune infiltration, as a new means of treatment in cancer

  2021cites this paper
• Cancer-associated fibroblasts and the tumor microenvironment in non-small cell lung cancer

  2021cites this paper
• A bird’s eye view of fibroblast heterogeneity: A pan‐disease, pan‐cancer perspective

  2021cites this paper
• Targeting and Reprograming Cancer-Associated Fibroblasts and the Tumor Microenvironment in Pancreatic Cancer

  2021cites this paper
• High expressions of CD10, FAP and GPR77 in CAFs are associated with chemoresistance and worse prognosis in gastric cancer

  2021cites this paper
• Cancer-Associated Fibroblasts as Players in Cancer Development and Progression and Their Role in Targeted Radionuclide Imaging and Therapy

  2021cites this paper
• Engineering T Cells to Survive and Thrive in the Hostile Tumor Microenvironment

  2021cites this paper
• University of Birmingham Fibroblasts as immune regulators in infection, inflammation and cancer

  2021cites this paper
• An ultra-high-affinity small organic ligand of fibroblast activation protein for tumor-targeting applications

  2021cites this paper
• Development of a Bispecific Antibody-Based Platform for Retargeting of Capsid Modified AAV Vectors

  2021cites this paper
• Fibroblasts Influence the Efficacy, Resistance, and Future Use of Vaccines and Immunotherapy in Cancer Treatment

  2021cites this paper
• Cancer-Associated Fibroblasts: Implications for Cancer Therapy

  2021cites this paper
• Association of cancer-associated fibroblasts and survival in malignant ovarian neoplasms

  2021cites this paper
• Therapeutic Potential of Antibody-Drug Conjugate-Based Therapy in Head and Neck Cancer: A Systematic Review

  2021cites this paper
• Fibroblasts as immune regulators in infection, inflammation and cancer

  2021cites this paper
• A novel anti-tumor/anti-tumor-associated fibroblast/anti-mPEG tri-specific antibody to maximize the efficacy of mPEGylated nanomedicines against fibroblast-rich solid tumor.

  2021cites this paper
• Bayesian cell-type deconvolution and gene expression inference reveals tumor-microenvironment interactions

  2020cites this paper
• Biomarkers for cancer-associated fibroblasts

  2020cites this paper
• Breast Fibroblasts and ECM Components Modulate Breast Cancer Cell Migration through the Secretion of MMPs in a 3D Microfluidic Co-Culture Model

  2020cites this paper